One company's quest for an antibody drug to fight COVID-19
On a Saturday afternoon in March as COVID-19 was bearing down on New York City, a dozen scientists anxiously crowded around a computer in a suburban drug company’s lab. They had spent weeks frantically getting blood from early survivors across the globe and from mice with human-like immune systems — all to test thousands of potential treatments.
Become a Subscriber!
You have read all of your free articles this month. Select a plan below to start your subscription today.
Already a subscriber? Login
